Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with E...
Company successfully meets key milestone with design lock that integrates and finalizes enhancements to its licensed Apex 6 Radiofrequency (“RF&rdq...
Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to treating cardiometabolic diseases driven by obesity, announced the pub...
UCB, a global biopharmaceutical company, announced that Epilepsia published findings from the final analysis of the long-term open-label extension (OLE) st...
GC Cell, under the leadership of CEO Sungyong Won, announced the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5...
Celltrion announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following approval by the U....
Ionis Pharmaceuticals, Inc. and Ono Pharmaceutical Co., Ltd (Ono), announced that the two companies have entered into a license agreement in whi...
Gilead Sciences, Inc. presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company...
Arvinas, Inc. announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulves...
ACTG, a global clinical trials network focused on HIV and other infectious diseases, announced new findings from the SLIM LIVER study (also known as A5371)...
CervoMed Inc. a clinical-stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), announced positive ...
Kodiak Sciences Inc. announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with diabetic r...
Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and...
Celltrion announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and only biosimila...
© 2025 Biopharma Boardroom. All Rights Reserved.
